Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9982895 | 0.86 | C5AR1 (0.42) | C5AR1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL9982413 | 0.85 | C5AR1 (0.43) | C5AR1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL9982723 | 0.84 | C5AR1 (0.51) | C5AR1MAPTALDH1A1CHRM1OPRM1 | |
| SCHEMBL9983006 | 0.81 | C5AR1 (0.49) | C5AR1MAPTALDH1A1MITFKMT2A | |
| SCHEMBL12067691 | 0.80 | C5AR1 (0.47) | C5AR1MAPTLMNAALDH1A1KMT2A | |
| SCHEMBL27909302 | 0.78 | MAPT (0.52) | MAPTL3MBTL1LMNAPOLBALDH1A1 | |
| SCHEMBL9982749 | 0.76 | C5AR1 (0.42) | C5AR1MAPTALDH1A1MITFKMT2A | |
| SCHEMBL12069072 | 0.74 | C5AR1 (0.50) | C5AR1MAPTLMNAALDH1A1KMT2A | |
| SCHEMBL9982630 | 0.74 | C5AR1 (0.56) | C5AR1ALDH1A1CHRM1OPRM1TSHR | |
| SCHEMBL9982715 | 0.73 | C5AR1 (0.42) | C5AR1MAPTLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | C5AR1 1212/4885MAPT 3004/4885L3MBTL1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.